Literature DB >> 7608792

Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome.

J Petäjä1, H Jalanko, C Holmberg, S Kinnunen, M Syrjälä.   

Abstract

A 16-year-old patient with relapsing nephrotic syndrome had three episodes of deep vein thrombosis after the age of 15 years. An autosomal inherited genetic abnormality of clotting factor V, resistance to activated protein C, was found. The clinical course showed that this resistance and the nephrotic syndrome potentiated each other as risk factors for deep vein thrombosis, and long-term anticoagulation was indicated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608792     DOI: 10.1016/s0022-3476(95)70266-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.

Authors:  A Ferreira-Gonzalez; L M Fisher; C M Lehman; M H Langley; D H Lofland; Q Xia; N X Nguyen; D Modesto; J B Willoughby; D S Wilkinson; C T Garrett
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

Review 2.  Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.

Authors:  U Nowak-Göttl; K Auberger; U Göbel; W Kreuz; R Schneppenheim; H Vielhaber; W Zenz; B Zieger
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

Review 3.  Cerebral sinovenous thrombosis and idiopathic nephrotic syndrome in childhood: report of four new cases and review of the literature.

Authors:  Joel Fluss; Denis Geary; Gabrielle deVeber
Journal:  Eur J Pediatr       Date:  2006-05-12       Impact factor: 3.183

4.  Prevalence of factor V Leiden in children with thrombo-embolism.

Authors:  I Aschka; V Aumann; F Bergmann; U Budde; W Eberl; S Eckhof-Donovan; S Krey; U Nowak-Göttl; R Schobess; A H Sutor; J Wendisch; R Schneppenheim
Journal:  Eur J Pediatr       Date:  1996-12       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.